Azienda Ospedaliera Universitaria Integrata Verona — Clinical Trial Site

30 Registered trials

11 Currently recruiting

Organisation

Azienda Ospedaliera Universitaria Integrata Verona

Location

Verona, Italy

Identifier

ORG-100041284

Address

Piazzale Ludovico Antonio Scuro 10, 37134, Italy

Departments

#2809: Diabetologia
Centro Ricerche Cliniche di Verona
CF
Cystic Fibrosis
Department of Medicine
Department of Neurology and Stroke Unit
Dip Neuroscienze e del movimento
Dipartimento Pediatria C - Broncopneumologia pediatrica Azienda
Dipartimento: SCIENZE CHIRURGICHE, ODONTOSTOMATOLOGICHE E MATERNO-INFANTILI
Medical Oncology
Medicina Generale B
N/A
Oncologia
Oncologia / Oncology
Oncologia Medica
Oncology
U.O.C Oncoematologia Pediatrica
U.O.C. Ematologia
U.O.C. Oncologia
Unità di Reumatologia
UOC di Ematologia
UOC Neuropsichiatria Infantile
UOC Oncoematologia Pediatrica
UOC Oncologia

Clinical trials at this site (30)

Search interface

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/… Not authorised

2022-500410-26-00 Cystic Fibrosis 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting

2023-503545-67-00 Tourette's Disorder 5 2024-04-30
Preventing caRdiovascular collapsE with VasoprEssors duriNg Tracheal IntubatiON: The PREVENTION Randomized Controlled Trial (PREVENTION tria… Recruiting

2023-503895-25-00 criticall illness 5 2024-08-01
A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting

2023-503219-14-01 systemic sclerosis associated interstitial lung disease 10 2024-05-22
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 5 2024-02-20
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meR… Recruiting

2022-500988-12-00 Advanced, naïve, Merkel cell carcinomas 4 2023-12-18
Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting

2022-502775-29-01 Early stage Follicular Lymphoma 5 2023-12-14
A study to assess efficacy of citicoline on visual field preservation in patients with glaucoma Recruiting

2022-502273-42-00 Glaucoma 5 2023-11-08
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate… Recruiting

2023-503295-25-00 Resectable biliary tract cancers 10 2023-10-31
A study to assess efficacy and safety of benralizumab in paediatric patients with severe eosinophilic asthma (severe asthma marked by high… Recruiting

2022-501344-14-00 Paediatric Patients with Severe Eosinophilic Asthma Ast 5 2023-06-05
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting

2022-500783-35-00 Acute Myeloid Leukemia 5 2022-12-06
A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He… Ended

2023-503422-39-00 Hepatocellular Carcinoma (HCC) 5 2023-10-20
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Myelodysplastic Syndrome (MDS) 5 2023-10-11
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended

2022-501463-40-01 Locally Advanced or Metastatic Cholangiocarcinoma 5 2023-05-03
(Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended

2022-500637-80-00 gastrointestinal stromal tumor 5 2023-03-28
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended

2022-501817-29-00 High Risk Non-muscle invasive bladder cancer 5 2018-11-27
A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Po… Ended

2022-500410-26-01 Cystic Fibrosis 4 2024-05-27